Vorinostat for uncontrolled Crohn’s or ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This early-phase study tests vorinostat to reduce gut inflammation in people with moderate-to-severe Crohn’s disease, ulcerative colitis, or certain colitis patterns linked to chronic granulomatous disease (CGD). It also looks at whether the study’s consent process is clear and understood before starting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old when you enroll.
- You have Crohn’s, ulcerative colitis, or CGD-related colitis confirmed by a scope (colonoscopy) or imaging, and you must be able to have a colonoscopy at the start.
- Your symptoms are actively “moderate to severe” based on specific scoring systems (CDAI for Crohn’s, Mayo score for ulcerative colitis, HBI for CGD colitis).
- Your disease is not controlled despite trying at least one past treatment type (steroids, immune-modulator medicines, anti-TNF, anti-integrin, JAK inhibitor, or IL-12/IL-23—called IL-23 in the criteria), or you cannot tolerate one of them.
- You can stay on certain stable background medicines (like some 5-ASA medicines or allowed doses of steroids) but you generally must avoid other specific biologic drugs and JAK/IL-23 therapies for set “washout” times.
- You have a main medical provider who can help coordinate your care during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.